Help
RSS
API
Feed
Maltego
Contact
Domain > immunology.no
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2018-11-02
188.94.218.238
(
ClassC
)
2024-09-09
193.58.250.63
(
ClassC
)
Port 80
HTTP/1.1 200 OKDate: Mon, 09 Sep 2024 13:46:49 GMTServer: Apache/1.3.39 (Unix) mod_ssl/2.8.30 OpenSSL/0.9.7e-p1Last-Modified: Thu, 18 Jan 2007 18:57:54 GMTETag: 14b5ed6-1d13-45afc332Accept-Ranges: bytesContent-Length: 7443Content-Type: text/html !DOCTYPE html PUBLIC -//W3C//DTD HTML 4.01//EN http://www.w3.org/TR/html4/strict.dtd>html>head>meta contenttext/html; charsetISO-8859-1 http-equivcontent-type>title>Center for studies of Immune Regulation, UiO/title>/head>body stylewidth: 728px; height: 158px;>form stylemargin-top: 58px; height: 112px; width: 565px; actionhttp://www.uio.no/perl/velgsok.pl> table stylewidth: 662px; height: 156px; border0 cellpadding0 cellspacing0> tbody> tr> td stylewidth: 19px; height: 83px;>/td>td styleheight: 83px;>/td>td stylewhite-space: nowrap; vertical-align: middle; text-align: left; background-color: rgb(204, 204, 255); width: 700px; height: 83px;> Logo img stylewidth: 531px; height: 63px; alt srcForslag%20CSIR%20banner2.jpg>/td>td stylevertical-align: bottom; background-color: rgb(51, 51, 153); width: 74px; height: 83px;>/td> /tr>tr>td stylewidth: 19px; background-color: rgb(204, 204, 255); height: 44px;>/td>td styleheight: 44px;>/td>td stylewidth: 700px; background-color: rgb(255, 255, 255); height: 44px;>img stylewidth: 773px; height: 42px; alt srcbluemesh2.gif>/td>td stylebackground-color: rgb(51, 51, 153); vertical-align: top; width: 74px; height: 44px;>br>/td>/tr>tr>td styleheight: 29px;>/td>td>/td>td styleheight: 29px; width: 700px;>a hrefhttp://www.med.uio.no/english/>span styletext-decoration: underline;>The Medical Faculty, University of Osl/span>span styletext-decoration: underline;>o/span>/a> a hrefhttp://www.med.uio.no/rh/immi/english/index.html>span styletext-decoration: underline;>Institute of Immunology/span>/a> a hrefhttp://www.med.uio.no/rh/english/>Faculty Division Rikshospitalet /a> /td>td styleheight: 29px; width: 74px;>/td>/tr> /tbody> /table>/form>form stylemargin-top: 58px; height: 112px; actionhttp://www.uio.no/perl/velgsok.pl> table stylewidth: 657px; height: 935px; border0 cellpadding0 cellspacing0> tbody> tr> td stylewhite-space: nowrap; text-align: left; width: 111px; vertical-align: top; background-color: rgb(204, 204, 255); height: 679px;>p classMsoNormal styletext-align: justify; font-family: Arial;>a hrefhttp://www.imbv.uio.no/cel/groups/obakke/Oddmund.htm>span stylefont-size: 12pt; color: black; langEN-GB>Bakke-group/span>/a>/p>p classMsoNormal styletext-align: justify; font-family: Arial;>a hrefhttp://www.immunol.net>span stylefont-size: 12pt; color: black; langEN-GB>Bogen-group/span>/a>/p>p classMsoNormal styletext-align: justify; font-family: Arial;>a hrefhttp://www.imbv.uio.no/cel/groups/sandlie/db02-info/internet/html/nr000016.html>span stylefont-size: 12pt; color: black; langEN-GB>Sandlie-group/span>/a>/p>p classMsoNormal styletext-align: justify; font-family: Arial;>a hrefhttp://www.med.uio.no/rh/immi/research/coeliac_disease/>span stylefont-size: 12pt; color: black; langEN-GB>Sollid-group/span>/a>/p>p classMsoNormal styletext-align: justify; font-family: Arial;>a hrefhttp://www.med.uio.no/rh/patologi/liipat/secretory_immunity/index.html>span stylefont-size: 12pt; color: black; langEN-GB>Johansen-group/span>/a>/p>p classMsoNormal styletext-align: justify; font-family: Arial;>a hrefhttp://www.med.uio.no/rh/patologi/liipat/secretory_immunity/index.html>span stylefont-size: 12pt; color: black; langEN-GB>/span>/a>/p>p classMsoNormal styletext-align: justify; font-family: Arial;>a hrefhttp://www.med.uio.no/rh/immi/english/index.html>span styletext-decoration: underline;>br>/span>/a>/p>/td>td stylewidth: 24px;>/td>td stylefont-family: Arial; height: 679px; width: 513px; vertical-align: top;>p classMsoNormal styletext-align: justify; font-family: Arial; margin-top: 0px; height: 47px;>span stylefont-size: 12pt; color: black; langEN-GB>This page is currently under span stylefont-weight: bold;>construction/span>/span>/p>p classMsoNormal styletext-align: justify; font-family: Arial;>span stylefont-size: 12pt; color: black; langEN-GB>The span stylefont-weight: bold;>Centre for Studies of Immune Regulation/span> has been selected as a Centre of Excellence by a hrefhttp://www.forskningsradet.no/servlet/Satellite?cPage&cid1138785830860&pagenameForskningsradetEngelsk%2FPage%2FStandardSidemal>The Research Council of Norway/a>, starting in 2007.There are five member-groups, Bakke-group, Bogen-group, Johansen-group,Sandlie-group and Sollid-group. All groups are located at a hrefwww.uio.no>The University of Oslo/a>./span>/p>br>p classMsoNormal styletext-align: justify; margin-top: 0px; height: 198px;>span stylefont-size: 12pt; font-family: "Times New Roman"; color: black; langEN-GB>span stylefont-weight: bold; font-family: Arial;>History/span>span stylefont-family: Arial;>. The three clinical immunology-oriented groups and the two basicimmunology/technology-oriented groups have been engaged in extensiveinteraction through the a hrefhttp://www.med.uio.no/rh/forskning/tematisk/cevi/>Centre for Vaccinology and Immunotherapy/a> (CEVI). CEVIwas established in 2001 as a thematic research group in the Faculty ofMedicine, University of Oslo, based on top evaluation among 37 applications. In 2005, CEVIreceived another excellent evaluation, and its mandate was extended. CEVI hasorganised an annual one-day synergy seminar emphasizing project presentation bydoctoral students and postdocs to promote student-initiated collaboration/span>./span>/p>p classMsoNormal styletext-align: justify;>big>big>big>span style langEN-GB>small>small>Objective/small>/small>/span>/big>/big>/big>br>span stylefont-size: 12pt; langEN-GB>Thescientific goal of the Centre is to identify mechanisms of immune dysregulationthat contribute to autoimmune and allergic disease. Three models of autoimmuneand allergic disease will be studied in detail to identify novel mechanismsamenable to therapeutic intervention. Applying this information, we willdevelop and implement innovative agents for use in immune intervention andtherapy. This work will involve a combination of basic research, research usinganimal and human disease models, and student training, all of which will becarried out by the multidisciplinary Centre. The Centre will be a collaborativeof two technology-oriented groups and three clinical immunology-oriented groupsin a st1:place w:ston>st1:placetype w:ston>University/st1:placetype> st1:placetype w:ston>Hospital/st1:placetype>/st1:place> environment. The fivegroups have complementary expertise and together possess an extensive array ofstate-of-the-art technologies that are integral to the studies. The Centre willalso bring in leading scientists from abroad. /span>span stylefont-size: 12pt; langEN-GB>o:p>/o:p>/span>/p>/td> /tr> /tbody> /table>/form>br stylefont-family: Arial;>form stylewidth: 677px; margin-top: 0px; height: 194px; actionhttp://www.uio.no/perl/velgsok.pl>br>/form>/body>/html>
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]